How Clinicians Diagnose Reglan-Related Tardive Dyskinesia

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure

If you or a loved one developed uncontrollable facial or body movements after taking Reglan, you may be wondering how doctors confirm the diagnosis. The medical community has long recognized the link between certain medications and movement disorders, and this understanding continues to guide clinical evaluation. This page outlines the diagnostic process and what current reports reveal about Reglan-related tardive dyskinesia.

Reglan and Tardive Dyskinesia: A Critical Link

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. The drug carries a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer treatment duration and higher total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, total treatment should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Statute of Limitations for Reglan Claims in Virginia

For patients in Virginia considering legal action related to Reglan-induced TD, the statute of limitations is a critical factor. Virginia law generally requires personal injury claims to be filed within two years of the date the injury was discovered or reasonably should have been discovered. This timeline can be complex in TD cases because symptoms may develop gradually after prolonged use, and the drug's ability to mask early signs may delay recognition. The boxed warning advises that TD risk increases with duration and cumulative dose, and that Reglan should be used for the shortest time possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring. The warning also states that in patients with diabetic gastroparesis, if longer-term use is unavoidable, routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to provide such monitoring may be relevant to claims of inadequate warnings or medical negligence. Settlement considerations for affected patients often involve the severity of TD, the duration of Reglan use, and the adequacy of warnings provided by prescribers and manufacturers. The boxed warning is a prominent FDA-mandated alert, but its presence does not guarantee that patients received or understood the risk. Evidence of prolonged use beyond 12 weeks without reassessment may support claims that the manufacturer or healthcare providers failed to adhere to labeled precautions. The timeline between exposure and documented harm is crucial: TD may appear months or years after starting Reglan, and symptoms can persist or become permanent even after discontinuation. Patients who develop TD after long-term use may have stronger claims if they can show that the drug was prescribed beyond the recommended duration without proper monitoring. In Virginia, the statute of limitations clock typically starts when the patient knew or should have known that TD was caused by Reglan. This can be challenging because TD symptoms may be misattributed to other conditions. Legal counsel can help determine the applicable filing deadline based on individual circumstances. Settlement amounts in Reglan TD cases have varied widely, depending on factors such as the severity of movement disorder, impact on daily functioning, and evidence of inadequate warnings. The FDA label explicitly states that Reglan can cause TD and that the drug is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This labeling may be used to argue that the manufacturer provided sufficient warning, but prescribers may still be liable for failing to adhere to usage guidelines. Patients in Virginia who believe they have developed TD from Reglan should seek medical evaluation to confirm the diagnosis and document the timeline of exposure. They should also consult with an attorney experienced in pharmaceutical litigation to assess the statute of limitations and potential for settlement. The boxed warning and other label sections provide clear evidence of the known risks, which can be used to support claims that the drug was used inappropriately or without adequate patient monitoring.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia claims in Virginia?

Virginia law generally requires personal injury claims to be filed within two years of the date the injury was discovered or reasonably should have been discovered. For TD cases, this can be complex because symptoms may develop gradually and the drug can mask early signs. It is crucial to consult an attorney to determine the applicable deadline based on individual circumstances.

Can I file a lawsuit if I developed tardive dyskinesia after taking Reglan for more than 12 weeks?

Yes, prolonged use beyond the recommended 12-week maximum may strengthen a claim, especially if there was no adequate monitoring. The FDA label warns that risk increases with duration and cumulative dose, and that Reglan should be used for the shortest time possible. Evidence of extended use without reassessment may support claims of inadequate warnings or negligence.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.